These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

110 related articles for article (PubMed ID: 17491581)

  • 1. Selective T-cell costimulation modulation: a new approach to treating rheumatoid arthritis.
    Strand V
    Am J Orthop (Belle Mead NJ); 2007 Mar; 36(3 Suppl):8, 13-4. PubMed ID: 17491581
    [No Abstract]   [Full Text] [Related]  

  • 2. Rheumatoid arthritis. Understanding joint damage and inflammation.
    Capriotti T
    Adv Nurse Pract; 2007 May; 15(5):61-2, 64-6, 94. PubMed ID: 20000214
    [No Abstract]   [Full Text] [Related]  

  • 3. New therapeutics that treat rheumatoid arthritis by blocking T-cell activation.
    MacKenzie NM
    Drug Discov Today; 2006 Oct; 11(19-20):952-6. PubMed ID: 16997147
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Biopharmaceuticals in the treatment of rheumatoid arthritis].
    Baslund B; Bendtzen K
    Ugeskr Laeger; 2008 Jun; 170(24):2108-10. PubMed ID: 18572481
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Psoriasiform lesions appearing in three patients with rheumatoid arthritis during therapeutic administration of abatacept, a selective inhibitor of T-cell costimulation.
    Konsta M; Rallis E; Karameris A; Stratigos A; Sfikakis PP; Iliopoulos A
    J Eur Acad Dermatol Venereol; 2012 Feb; 26(2):257-8. PubMed ID: 22280512
    [No Abstract]   [Full Text] [Related]  

  • 6. Tumor necrosis factor inhibitors for rheumatoid arthritis.
    Roos JC; Ostor AJ
    N Engl J Med; 2006 Nov; 355(19):2046-7; author reply 2048. PubMed ID: 17093259
    [No Abstract]   [Full Text] [Related]  

  • 7. [TNF-alpha antibody in rheumatoid arthritis. Efficacy-risk relationship is positively evaluated].
    MMW Fortschr Med; 2002 May; 144(20):65. PubMed ID: 12119893
    [No Abstract]   [Full Text] [Related]  

  • 8. Increase of peripheral CXCR3 positive T lymphocytes upon treatment of RA patients with TNF-alpha inhibitors.
    Aeberli D; Seitz M; Jüni P; Villiger PM
    Rheumatology (Oxford); 2005 Feb; 44(2):172-5. PubMed ID: 15509629
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The evolving use of tumor necrosis factor inhibitors in rheumatoid arthritis.
    Kavanaugh A; Cohen S; Cush JJ
    J Rheumatol; 2004 Oct; 31(10):1881-4. PubMed ID: 15468347
    [No Abstract]   [Full Text] [Related]  

  • 10. Immunological therapies for rheumatoid arthritis.
    Edwards CJ
    Br Med Bull; 2005; 73-74():71-82. PubMed ID: 16174791
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Results of anakinra treatment in rheumatoid arthritis patients previously treated with tumor necrosis factor alpha blockade: comment on the article by Buch et al.
    Saxne T; Larsson L; Geborek P
    Arthritis Rheum; 2004 Sep; 50(9):3049-50; author reply 3050-1. PubMed ID: 15457477
    [No Abstract]   [Full Text] [Related]  

  • 12. Is there a pharmacoeconomic argument supporting the use of tumor necrosis factor inhibitors in early rheumatoid arthritis?
    Kavanaugh A
    Nat Clin Pract Rheumatol; 2006 Jul; 2(7):346-7. PubMed ID: 16932716
    [No Abstract]   [Full Text] [Related]  

  • 13. T-cell agents in the treatment of rheumatoid arthritis - 2011 update.
    Solomon GE
    Bull NYU Hosp Jt Dis; 2011; 69(3):230-2. PubMed ID: 22035434
    [No Abstract]   [Full Text] [Related]  

  • 14. Early rheumatoid arthritis.
    Machold KP; Nell V; Stamm T; Aletaha D; Smolen JS
    Curr Opin Rheumatol; 2006 May; 18(3):282-8. PubMed ID: 16582693
    [TBL] [Abstract][Full Text] [Related]  

  • 15. What can we learn from treatment-induced changes in rheumatoid factor and anti-citrullinated Peptide antibodies?
    Bobbio-Pallavicini F; Caporali R; Bugatti S; Montecucco C
    J Rheumatol; 2008 Oct; 35(10):1903-5. PubMed ID: 18843754
    [No Abstract]   [Full Text] [Related]  

  • 16. Rheumatoid arthritis therapy after tumor necrosis factor and interleukin-1 blockade.
    Redlich K; Schett G; Steiner G; Hayer S; Wagner EF; Smolen JS
    Arthritis Rheum; 2003 Dec; 48(12):3308-19. PubMed ID: 14673982
    [No Abstract]   [Full Text] [Related]  

  • 17. Emerging biologic drugs for the treatment of rheumatoid arthritis.
    Puppo F; Murdaca G; Ghio M; Indiveri F
    Autoimmun Rev; 2005 Nov; 4(8):537-41. PubMed ID: 16214092
    [TBL] [Abstract][Full Text] [Related]  

  • 18. T-cell agents in the treatment of rheumatoid arthritis - 2012 update.
    Solomon GE
    Bull NYU Hosp Jt Dis; 2012; 70(3):191-4. PubMed ID: 23259627
    [No Abstract]   [Full Text] [Related]  

  • 19. Will our current success in treating rheumatoid arthritis hinder new drug development? That is the question!!
    Weinblatt ME
    Ann Rheum Dis; 2005 Nov; 64(11):1529-31. PubMed ID: 16126790
    [No Abstract]   [Full Text] [Related]  

  • 20. Anti-cyclic citrullinated peptide antibodies in patients with rheumatoid arthritis treated with anti-tumour necrosis factor agents.
    Russell AS; Maksymowych WP; de Silva M
    Ann Rheum Dis; 2005 Dec; 64(12):1807. PubMed ID: 16284357
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.